Multiple myeloma in patients admitted the provincial hospital of Pinar del Río
Keywords:
MULTIPLE MYELOMA, NEOPLASMS, PLASMA CELLS, BLOOD CELLS, BONE MARROW.Abstract
Introduction: multiple myeloma is a tumor derived from plasma cells, a type of blood cell in the bone marrow that produces antibodies to fight the germs.
Objective: to describe the clinical epidemiological behavior of multiple myeloma in patients hospitalized in the Internal Medicine and Geriatrics services at Dr. León Cuervo Rubio Clinical Surgical Teaching Hospital during the years 2017 and 2018, in Pinar del Río.
Methods: an observational, descriptive, longitudinal and prospective study was conducted. The target group included 31 patients diagnosed with multiple myeloma; the sample comprised 25 patients by simple random sample.
Results: a prevalence of the disease was observed in male patients and in the age group from 70-79 years old. The main comorbidities and complications presented by patients with multiple myeloma were anemia in all of them, and kidney failure.
Conclusions: knowledge of the clinical epidemiological behavior of multiple myeloma is important in order to achieve a timely and comprehensive diagnosis to improve the patient’s quality of life.
Downloads
References
1. Moreau P, San Miguel J, Ludwig H, Schouten H, Mohty M, Dimopoulos M, et al. Multiple Myeloma: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. Ann Oncol [Internet]. 2013 [citado 22/06/2019]; 24(supl6): [aprox. 4 p.]. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/23956208
2. Medina S, Espino M, Blanchard MJ. Marcadores pronósticos en pacientes con gammapatía monoclonal de significado incierto. Inmunología [Internet]. 2014 [citado 2/06/2019]; 33(1): [aprox. 4 p.]. Disponible en: https://www.elsevier.es/es-revista-inmunologia-322-articulo-marcadores-pronosticos-pacientes-con-gammapatia-S0213962613000796
3. Guidelines for the diagnosis and management of multiple myeloma 2014 [Internet]. British Society for Haematology & UK Myeloma Forum; 2019 [citado 18/08/2019]. Disponible en: https://www.partnershipagainstcancer.ca/db-sage/sage20142135/#
4. Ramos Ortega F. Incidencia [Internet]. España: Sociedad española de Hematología y Hemoterapia. Asociación Española contra el cáncer; 2015 [citado 11/03/2019]. Disponible en: https://www.aecc.es/es/todo-sobre-cancer/tipos-cancer/mieloma-multiple/evolucion-mieloma-multiple
5. Pedroza Vázquez A, Zamora Palma A. Utilidad de pruebas de laboratorio en el diagnóstico de mieloma múltiple. Rev Latinoam Patol Clin Med Lab [Internet]. 2015 [citado 22/06/2019]; 62(1): [aprox. 7 p.]. Disponible en: http://www.medigraphic.com/pdfs/patol/pt-2015/pt151i.pdf
6. Alfonso Hernández L. Mieloma múltiple [Internet]. La Habana: Consultas Médicas; 2018 [citado 25/01/2018]. Disponible en: http://consultas.cuba.cu/consultas.php?id_cat=3&letr=m&id_cons=318&pagina=1
7. Bravo García-Morato M. Laboratory guidelines for the diagnosis and follow-up of patients with monoclonal gammopathies. Rev Clínica Española [Internet]. 2016 Abr [citado 13/09/2019]; 216(3): [aprox. 7 p.]. Disponible en: http://www.revclinesp.es/es/guialaboratorio-el-diagnosticoseguimiento/articulo/S0014256515002271/
8. Calvo Barbado DM, Delgado Martínez I. Formulario Nacional de Medicamentos. 4ta.ed. La Habana꞉ Ecimed; 2014. 820p.
9. González-Calle V, Fonseca R. Retos y avances hacia la medicina de precisión en el mieloma múltiple. Medicina (B. Aires) [Internet]. 2017 Jun [citado 17/12/2018]; 77(3): [aprox. 4 p.]. Disponible en: http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S0025-76802017000300011&lng=es
10. Suárez González A, González Gil A, García Menéndez R, Álvarez Vega N, Estrada Vaillant A, Hernández Ugalde F. Comportamiento de las inmunoglobulinas en el seguimiento de pacientes con mieloma múltiple. Hospital Universitario Comandante Faustino Pérez. Matanzas. Rev Méd Electrón [Internet]. 2018 Feb [citado 23/06/2019]; 40(1): 69-80. Disponible en: http://www.revmedicaelectronica.sld.cu/index.php/rme/article/view/2501/3691
11. Ramón Rodríguez LG, Rivera-Keeling C, Arencibia-Núñez A. Caracterización clínica y de laboratorio del mieloma múltiple en el Instituto de Hematología e Inmunología. Rev Cubana Hematol Inmunol Hemoter [Internet]. 2013 Dic [citado 29/05/2019]; 29(4): [aprox. 15 p.]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-02892013000400008&lng=es
12. Agreda Pantoja A, Chao Pereira C, Hernández Barraza D, Roca Campaña V. Mieloma múltiple en paciente joven. Rev cubana med [Internet]. 2016 Dic [citado 17/12/2018]; 55(4): [aprox. 3 p.]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75232016000400006&lng=es
13. da Silva Ferreira K, Rafael Maciel JF, de Souza Rego Pinto Carvalho DP, Campos de Azevedo I, Fortes Vitor A, Ferreira Júnior MA. Clinical characterization and survival of patients with multiple myeloma in a state of northeast brazilian. Rev Cubana Hematol Inmunol Hemoter [Internet]. 2017 Jun [citado 17/12/2018]; 33(2): [aprox. 9 p.]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-02892017000200009&lng=es
14. FEAD. Hematólogos señalan que tratamiento del mieloma múltiple mejora la respuesta antitumoral y tasas de larga supervivencia [Internet]. MADRID: EUROPA PRESS ,5 sept. 2018 [citado 17/12/2018]. Disponible en: https://www.saludigestivo.es/hematologos-senalan-que-tratamiento-del-mieloma-multiple-mejora-la-respuesta-antitumoral-y-tasas-de-larga-supervivencia/
Downloads
Published
How to Cite
Issue
Section
License
Authors who have publications with this journal agree to the following terms: Authors will retain their copyrights and grant the journal the right of first publication of their work, which will be publication of their work, which will be simultaneously subject to the Creative Commons Attribution License (CC-BY-NC 4.0) that allows third parties to share the work as long as its author and first publication in this journal are indicated.
Authors may adopt other non-exclusive license agreements for distribution of the published version of the work (e.g.: deposit it in an institutional telematic archive or publish it in a volume). Likewise, and according to the recommendations of the Medical Sciences Editorial (ECIMED), authors must declare in each article their contribution according to the CRediT taxonomy (contributor roles). This taxonomy includes 14 roles, which can be used to represent the tasks typically performed by contributors in scientific academic production. It should be consulted in monograph) whenever initial publication in this journal is indicated. Authors are allowed and encouraged to disseminate their work through the Internet (e.g., in institutional telematic archives or on their web page) before and during the submission process, which may produce interesting exchanges and increase citations of the published work. (See The effect of open access). https://casrai.org/credit/